SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

RyCarma Reports First Patient Dosed in Phase 2 Surlorian Trial

RyCarma said the first patient has been dosed in its Phase 2 clinical trial of surlorian for RYR1-related myopathy.

Related stories